#Biotech

In Kigali this summer, a carefully watched clinical trial out of Umlazi, South Africa, offered the most hopeful signal in years that remission from HIV might be achievable for more people, including those in Africa where the virus has forged a heavy social and economic burden. The study, part of a broader push to develop a cure rather than lifelong treatment, used a two-pronged strategy: a drug to wake latent HIV and a one-time infusion of broadly neutralizing antibodies to clear what is surfaced. The result? Among 20 women enrolled, four stayed in remission for a period after stopping antiretroviral therapy; one later experienced a rebound, while others chose to resume treatment for practical reasons. The lead patient in the cohort, Anele, has remained off treatment for more than two years and HIV-free, though researchers stop short of declaring a universal cure. The findings are not a slam dunk, but they are a toehold—enough to renew optimism that cures might eventually come from trials that reflect the realities of people most affected by HIV in Africa and beyond.

A new international study outlines a potential breakthrough for autoimmune conditions, including type 1 diabetes. Researchers describe BiTS, a protein-based therapy that may halt disease progression by precisely silencing problematic T cells. The work, conducted across institutions in New York, China, and Zhejiang, demonstrates in animal models how targeted immune suppression can curb disease while preserving overall immunity.

The findings resonate with Thailand, where autoimmune diseases are placing a growing burden on patients and families who depend on long-term medications. Autoimmune conditions occur when the immune system mistakenly attacks healthy tissues. Current treatments mainly control symptoms and carry notable side effects, underscoring the need for therapies that address root causes.